Field evolution (2015–2026)
Scrub through eras of EV therapeutic manufacturing hype, regulatory scrutiny, platform setbacks, and selective biologics-focused opportunity.
Three-lane view
Field state
EVs framed as safer cell-free substitutes for MSCs and other therapeutic cells
Manufacturing
Mostly ultracentrifugation, conditioned media, variable research-grade workflows
Venture read
Interesting science, poor product definition
Three-lane view
Field state
MISEV guidance and more rigorous characterization
Manufacturing
Movement toward TFF, SEC, closed culture systems
Venture read
Translation begins, but CMC risk becomes obvious
Three-lane view
Field state
COVID-era hype and unapproved exosome clinics; legitimate engineered EV companies advance
Manufacturing
Need for sterility, viral safety, release assays, potency, identity, purity
Venture read
Regulatory scrutiny rises; exosome marketing becomes a red flag
Three-lane view
Field state
Codiak failure cools engineered exosome platform enthusiasm
Manufacturing
Better analytics, persistent batch heterogeneity and potency problems
Venture read
Survivors need narrow indications and disciplined CMC
Three-lane view
Field state
Field shifts toward EVs as biologics/platforms rather than generic regenerative products
Manufacturing
Increasing focus on bioreactors, cell banking, defined media, orthogonal characterization
Venture read
Selective opportunity, not broad platform euphoria